Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5‐FU vs. methyl‐CCNU plus bolus weekly 5‐FU. A southwest oncology group study

Laurence H. Baker, Robert W. Talley, Richard Matter, Daniel E. Lehane, B. W. Ruffner, Stephen E. Jones, Francis S. Morrison, Ronald L. Stephens, Edmund A. Gehan, Vainutis K. Vaitkevicius

Research output: Contribution to journalArticle

92 Scopus citations

Abstract

In a randomized and stratified study, 294 patients with advanced gastrointestinal cancer were treated either with 5 fluorouracil (5 FU) 400 mg/m 2 weekly intravenously (i.v.) or 5 FU 400 mg/m 2 i.v. weekly plus methyl CCNU 175 mg/m 2 orally (p.o.) every 6 weeks. The response rate in colorectal cancer with 5 FU was 9.5% while the two drug treatment produced a response of 31.8% (p=.009). The response in all gastrointestinal cancers to 5 FU was 10.6% as compared with 29.3% for the combination (p=.012). All responses were partial. The two drug regimen is more effective and more toxic than weekly 5 FU therapy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCancer
Volume38
Issue number1
DOIs
StatePublished - Jul 1976

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5‐FU vs. methyl‐CCNU plus bolus weekly 5‐FU. A southwest oncology group study'. Together they form a unique fingerprint.

Cite this